Lantern Pharma Inc.
LTRN
$3.62
-$0.18-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.18M | -4.33M | -4.54M | -5.88M | -4.51M |
| Total Depreciation and Amortization | 54.30K | 53.50K | 52.40K | 51.20K | 4.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 208.00K | -41.60K | 39.70K | 538.90K | -166.60K |
| Change in Net Operating Assets | -656.80K | 381.90K | 69.10K | 1.31M | -914.30K |
| Cash from Operations | -4.57M | -3.94M | -4.38M | -3.97M | -5.58M |
| Capital Expenditure | -600.00 | 0.00 | -1.20K | -3.10K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.93M | 3.59M | 3.24M | 3.45M | 683.40K |
| Cash from Investing | 5.93M | 3.59M | 3.24M | 3.45M | 680.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 971.80K | -- | -- | 0.00 | 12.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 971.80K | -- | -- | 0.00 | 12.00K |
| Foreign Exchange rate Adjustments | -300.00 | 27.90K | 2.80K | -67.20K | 16.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.33M | -316.20K | -1.13M | -591.70K | -4.87M |